Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures

Recruiting now · Phase 4

Conditions studied: Soft Tissue Defects, Soft Tissue Wounds, Traumatic Soft Tissue Defect

In brief

Demonstrate faster tissue coverage of exposed structures using OFM in combination with negative pressure wound therapy (NPWT), versus NPWT alone

Key facts

Study ID

NCT07385313

Run by

Aroa Biosurgery Limited

People needed

30

Starts

2026-03-31

Expected to finish

2027-04-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients will be considered eligible for the study based on the following criteria:
• Willing and able to provide written informed consent and to comply with the requirements of the Clinical Investigational Plan
• Male or female patients aged 18 years or above
• Patient is requiring reconstruction of a full thickness soft tissue defect, that includes exposed structures (bone, tendon, or neurovascular), upper or lower extremity.
• Total defect size, range 25 to 800 cm2

You may not qualify if…

• Patients will be excluded from the study based on the following criteria:
• Patients with known sensitivity to ovine (sheep) derived material
• Pregnant or lactating females.
• Patients who are prisoners.
• Patients who are likely not to complete the study.
• Patients who, in the opinion of the Investigator, are unlikely to comply with the protocol.
• Patients currently participating in or have participated in another clinical study within the past 30 days prior to enrolment that at the discretion of the Investigator makes them unsuitable for inclusion in the study.
• Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study.
• Any medical condition, recent treatment or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study.
• Obesity (BMI>45)
• Blood glucose ≥350 mg/dL at admission
• History of chronic peripheral vascular disease
• Current immunosuppression
• Recent neoadjuvant chemotherapy or radiotherapy
• Previous or concurrent application of a cell/tissue-based product (CTP, or skin substitute) at the wound site within 30 days of the Screening Visit
• Defect is a third degree burn

Where it is running

• University of Colorado-Anschutz Medical Campus — Aurora, Colorado, United States (enrolling)
• The University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.